Relevant Scientific Publications.

What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise. Burton DR. Version 2. Cold Spring Harb Perspect Biol. 2017 Nov 1; 9(11):a030262. doi: 10.1101/cshperspect.a030262.
IAVI and Scripps Research have a successful history of discovering highly broad and potent neutralising antibodies against HIV and have built an antibody discovery platform that is readily applicable to other disease areas. The articles highlighted in this section provide the context that has informed the SRPNTS approach towards generating humanised monoclonal antibodies for eventual next-generation snakebite therapy(ies).
Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Sok D, Le KM, Vadnais M, Saye-Francisco KL, Jardine JG, Torres JL, Berndsen ZT, Kong L, Stanfield R, Ruiz J, Ramos A, Liang CH, Chen PL, Criscitiello MF, Mwangi W, Wilson IA, Ward AB, Smider VV, Burton DR. Nature. 2017 Aug 3; 548(7665):108-111. doi: 10.1038/nature23301.
Recent progress in broadly neutralizing antibodies to HIV. Sok D, Burton DR. Nat Immunol. 2018 Nov; 19(11):1179-1188. doi: 10.1038/s41590-018-0235-7.
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Burton DR, Hangartner L. Annu Rev Immunol. 2016 May 20; 34:635-59. doi: 10.1146/annurev-immunol-041015-055515.
SRPNTS researchers based at LSTM, N-SRIC, K-SRIC, and IISc have led the snakebite field in generating key data assessing snake venom toxin proteomes, transcriptomes, as well as the efficaciousness of existing commericial antivenoms. The articles highlighted here capture the work and contributions made by our SRPNTS researchers prior to joining and during our partnership.
Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis. Cardoso, F.C., Ferraz, C.R., Arrahman, A., Xie, C., Casewell, N.R., Lewis, R.J. and Kool, J. Frontiers in Ecology and Evolution, 7, p.218. 2019; doi: org/10.3389/fevo.2019.00218.
Beyond the ‘big four’: Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies. Laxme, R.S., Khochare, S., de Souza, H.F., Ahuja, B., Suranse, V., Martin, G., Whitaker, R., and Sunagar, K. PLoS neglected tropical diseases. 2019; 13(12), p.e0007899.
Signs, symptoms and treatment of envenomation. Boyer, L., Alagón, A., Fry, B.G., Jackson, T.N.W., Sunagar, K. and Chippaux, J.P. Venomous Reptiles and Their Toxins: Evolution, Pathophysiology, and Biodiscovery; Fry, BG, Ed, pp.32-60. 2015. 
Pre-clinical assays predict pan-African Echis viper efficacy for a species-specific antivenom. Casewell, N.R., Cook, D.A., Wagstaff, S.C., Nasidi, A., Durfa, N., Wüster, W. and Harrison, R.A. PLoS Negl Trop Dis, 4(10), p.e851. 2010. Doi: 10.1371/journal.pntd.0000851.
Analysis of camelid IgG for antivenom development: Immunoreactivity and preclinical neutralisation of venom-induced pathology by IgG subclasses, and the effect of heat treatment. Cook DA, Samarasekara CL, Wagstaff SC, Kinne J, Wernery U, Harrison RA. Toxicon. 2010 Sep 15;56(4):596-603. Doi: 10.1016/j.toxicon.2010.06.004.
Snake envenoming: a disease of poverty. Harrison, R.A., Hargreaves, A., Wagstaff, S.C., Faragher, B. and Lalloo, D.G. PLoS Negl Trop Dis, 3(12), p.e569. 2009.
Bioinformatics and multiepitope DNA immunization to design rational snake antivenom. Wagstaff SC, Laing GD, Theakston RD, Papaspyridis C, Harrison RA. Version 2. PLoS Med. 2006 Jun; 3(6):e184. Doi: 10.1371/journal.pmed.0030184.